| Theme | Evolution in Management of Renal Anemia | |
|---|---|---|
| Title | Renal anemia and new concept concerning mutual interaction between heart failure, renal failure and anemia | |
| Publish Date | 2008/01 | |
| Author | Masashi Suzuki | Kidney Center, Shinraku-En Hospital |
| [ Summary ] | Anemia occurs even in the early stages of chronic kidney disease (CKD). The pathogenesis of renal anemia depends basically on a relative lack of erythropoietin (EPO) production in the kidnies. The advent of recombinant human EPO shifted anemia from a burdensome condition to a controllable complication, along with improvements in ADL and QOL for CKD patients. Recently, a new concept concerning mutual interactions between heart failure, renal failure and anemia was proposed and termed “Cardio-Renal Anemia syndrome”. The concept implies that management of renal anemia will slow CKD progression, as well as decrease death from heart failure. Furthermore, EPO has been recognized to have potential effects on angiogenesis, and protection of nervous tissue, cardiac muscle and kidnies from ischemic attacks. Some newly developed erythropoiesis stimulating agents (ESA) activate EPO receptors for longer times than the native EPO dose. Another newly designed artificial peptide also activates EPO receptors. These new ESAs will change the clinical management of anemia in CKD patients. |
|